Biocon Limited’s Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025. Critically, the Board also granted in-principle approval to acquire the remaining ~2% equity share capital of its material subsidiary, Biocon Biologics Limited (BBL), from employees and other shareholders, paving the way for BBL to become a wholly-owned subsidiary (WOS). The consideration for this acquisition will be through a preferential allotment of Biocon’s equity shares.
Outcome of the Board Meeting
The Board of Directors of Biocon Limited, following their meeting on Thursday, February 12, 2026, inter alia, approved two key matters:
- The unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31, 2025, prepared under Ind-AS.
- In-principle approval for the acquisition of the remaining ~2% of the paid-up equity share capital of Biocon Biologics Limited (BBL) on a fully diluted basis from Group employees and other shareholders.
The Board Meeting commenced at 4:45 P.M. and concluded at 6:45 P.M.
Full Integration of Biocon Biologics (BBL)
This proposed acquisition finalizes the full integration of BBL with the Company. Previous communications indicated the stake was increasing to ~98%. The remaining stake acquisition will result in BBL becoming a Wholly Owned Subsidiary (WOS) of Biocon Limited.
The consideration for acquiring these BBL shares will be settled via a preferential allotment of Biocon’s equity shares, as per relevant SEBI regulations. This proposal is subject to necessary shareholder and statutory approvals.
Standalone Financial Highlights (Q3 FY26 vs Q3 FY25)
Reviewing the unaudited standalone financial results (Rs. in Million):
- Total Income: Increased from 6,270 (3 months ended Dec 31, 2024) to 6,961 (3 months ended Dec 31, 2025).
- Total Income (9M): Rose from 17,773 (9 months ended Dec 31, 2024) to 20,116 (9 months ended Dec 31, 2025).
- Net Profit/(Loss) for the period (9M): Improved significantly from a loss of (138) million to a profit of 5,881 million.
- Diluted EPS (9M): Moved from (0.11) to 4.91.
Consolidated Financial Highlights (Q3 FY26 vs Q3 FY24)
On a consolidated basis (Rs. in Million):
- Revenue from operations (Q3): Increased from 28,580 to 32,114.
- Total Income (Q3): Increased from 38,214 to 42,903.
- Profit/(loss) for the period (9M): Increased from 1,702 to 1,702 (The 9-month figure remains consistent, suggesting exceptional items impacted the base for comparison).
- Total Comprehensive Income (9M): Increased from 1,377 to 12,402.
Segment Performance Overview (Consolidated)
The primary segments reported the following Profit Before Tax from each segment for the 9 months ended December 31, 2025 (Rs. in Million):
- Generics: Loss of (1,225).
- Biosimilars: Profit of 3,368 (compared to 10,485 in the previous corresponding period).
- CRDMO: Profit of 2,855 (compared to 3,874 previously).
Overall, Profit before tax and exceptional items stood at 5,229 million for the nine-month period.
Key Post-Reporting Events (Subsequent to Dec 31, 2025)
Subsequent events impacting capital structure and acquisitions include:
- On January 14, 2026, the Company raised Rs. 41,500 million via QIP to acquire BBL shares and for general corporate purposes.
- On January 05, 2026, the Company acquired 112,860,496 BBL equity shares from Serum Institute Life Sciences, Tata Capital Growth Fund II, and Activ Pine LLP, issuing 79,312,534 Biocon equity shares in exchange.
- Early redemption of NCDs worth Rs. 6,795 million occurred on January 05, 2026.
Source: BSE
